Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Josep M. Llovet, MD
Josep M. Llovet, MD, Mount Sinai
Articles by Josep M. Llovet, MD
LEAP-012: PFS Benefit With Pembrolizumab, Levatinib, and TACE vs TACE Alone
Josep M. Llovet, MD
GI Cancer
|
March 13, 2025
Dr. Josep Llovet discusses promising data, including higher PFS and OS, in metastatic liver cancer from the LEAP-012 trial.
View More
LEAP-002: IO/VEGF Versus IO/IO Versus IO/TKI
Josep M. Llovet, MD
Hepatocellular Carcinoma
|
March 13, 2025
Drs. Llovet and Finn consider how LEAP-002 adds to the debate around IO/VEGF, IO/IO, and IO/TKI for aHCC.
View More
LEAP-002: Lenvatinib Plus Pembrolizumab for First-Line Advanced HCC?
Josep M. Llovet, MD
Hepatocellular Carcinoma
|
March 13, 2025
Drs. Llovet and Finn provide a high-level understanding of LEAP-002, looking at lenvatinib/pembrolizumab for 1L aHCC.
View More